Business
Inventiva reports preliminary 2025¹ fiscal year financial results
Cash and cash equivalents at €99.3 million, and €131.6 million in short-term deposits2 as of December 31, 2025Revenues of €4.5 million in 2025Completed a U.S. registered public offering for gross proceeds of approximately $172.5 million (€149 million3)Cash runway expected until the middle of the first quarter of 20274 Daix (France), New York City (New York, United States), February 17, 2026 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceu
About this update from Inventiva Sa
[{"type":"image","alt":"INVENTIVA","displaySize":"","headline":null,"caption":"INVENTIVA","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":142,"url":"https://media.zenfs.com/en/globenewswire.com/fef5472de2e52c88120abbdb39dcd123"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/IFR.Gz27ItPSlaHquTiPVA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE5OTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/fef5472de2e52c88120abbdb39dcd123","width":300,"height":142}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Cash and cash equivalents at €99.3 million, and €131.6 million in short-term deposits2 as of December 31, 2025","length":110,"tagName":"p"}]},{"val":[{"type":"text","content":"Revenues of €4.5 million in 2025","length":32,"tagName":"p"}]},{"val":[{"type":"text","content":"Completed a U.S. registered public offering for gross proceeds of approximately $172.5 million (€149 million3)","length":110,"tagName":"p"}]},{"val":[{"type":"text","content":"Cash runway expected until the middle of the first quarter of 20274","length":67,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":319,"olType":false},{"type":"text","content":"Daix (France), New York City (New York, United States), February 17, 2026 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), today reported its certain preliminary unaudited financial results for the full year ending December 31, 2025, including cash, cash equivalents, and revenues.","length":507,"tagName":"p"},{"type":"text","content":"Cash and cash equivalents","length":25,"tagName":"p"},{"type":"text","content":"As of December 31, 2025, the Company's cash and cash equivalents amounted to €99.3 million and its short-term deposits2 to €131.6 million, compared to cash and cash equivalents of €96.6 million as of December 31, 2024.","length":222,"tagName":"p"},{"type":"text","content":"Net cash used in operating activities amounted to (€104.6) million in 2025, compared to (€85.9) million in 2024, representing an increase of 22%. R&D expenses, mainly related to the development of lanifibranor in MASH, amounted to €86.9 million in 2025, down 4% fro...